Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
作者信息
Collins R, Baigent C, Sandercock P, Peto R
机构信息
ICRF/BHF/MRC Clinical Trial Service Unit, Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford.
出版信息
BMJ. 1994 Nov 5;309(6963):1215-7. doi: 10.1136/bmj.309.6963.1215.
Abstract
摘要
相似文献
1
Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.抗血小板治疗用于血栓预防：需要仔细考量随机试验的证据。抗血小板试验协作组。
BMJ. 1994 Nov 5;309(6963):1215-7. doi: 10.1136/bmj.309.6963.1215.
2
Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验协作概述——III：手术和内科患者中抗血小板预防对静脉血栓形成和肺栓塞的降低作用。抗血小板试验协作组
BMJ. 1994 Jan 22;308(6923):235-46.
3
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?用于血栓预防的抗血小板治疗：是前进还是后退？
BMJ. 1994 Nov 5;309(6963):1213-5. doi: 10.1136/bmj.309.6963.1213.
4
Anticoagulants versus antiplatelet agents for acute ischaemic stroke.急性缺血性卒中抗凝剂与抗血小板药物的比较
Cochrane Database Syst Rev. 2002(4):CD003242. doi: 10.1002/14651858.CD003242.
5
6
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I：各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
7
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.双嘧达莫用于预防血管疾病患者的中风及其他血管事件。
Cochrane Database Syst Rev. 2003(1):CD001820. doi: 10.1002/14651858.CD001820.
8
[Meta-analysis of antiaggregant therapy trials. Proposal of an additional reading key].[抗聚集治疗试验的荟萃分析。一种额外阅读关键的提议]
Recenti Prog Med. 1998 Oct;89(10):494-500.
9
Who needs antiplatelet therapy?谁需要抗血小板治疗？
Br J Gen Pract. 1996 Jun;46(407):367-70.
10
[Thromboembolic risk].[血栓栓塞风险]
Minerva Anestesiol. 1988 Oct;54(10):405-12.
引用本文的文献
1
Critical appraisal of the role of pegloticase in the management of gout.聚乙二醇化尿酸酶在痛风治疗中作用的批判性评价
Open Access Rheumatol. 2012 Jun 26;4:63-70. doi: 10.2147/OARRR.S17431. eCollection 2012.
2
Cohort feasibility study of an intermittent pneumatic compression device within a below-knee cast for the prevention of venous thromboembolism.一项关于在膝下石膏中使用间歇性气动压缩装置预防静脉血栓栓塞的队列可行性研究。
BMJ Open. 2016 Oct 4;6(10):e012764. doi: 10.1136/bmjopen-2016-012764.
3
Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.低剂量阿司匹林、非甾体抗炎药、选择性环氧化酶-2抑制剂与乳腺癌复发
Epidemiology. 2016 Jul;27(4):586-93. doi: 10.1097/EDE.0000000000000480.
4
Systemic inflammatory response syndrome and platelet count ≥250×10(9) are associated with venous thromboembolic disease.全身炎症反应综合征和血小板计数≥250×10⁹与静脉血栓栓塞性疾病相关。
Int J Gen Med. 2015 Jan 14;8:37-40. doi: 10.2147/IJGM.S72259. eCollection 2015.
5
Platelets are dominant contributors to hypercoagulability after injury.血小板是损伤后高凝状态的主要贡献者。
J Trauma Acute Care Surg. 2013 Mar;74(3):756-62; discussion 762-5. doi: 10.1097/TA.0b013e3182826d7e.
6
Aspirin and clopidogrel for prevention of ischemic stroke.阿司匹林和氯吡格雷预防缺血性脑卒中。
Curr Neurol Neurosci Rep. 2013 Feb;13(2):327. doi: 10.1007/s11910-012-0327-y.
7
Cyclooxygenase products and atherosclerosis.环氧化酶产物与动脉粥样硬化
Drug Discov Today Ther Strateg. 2008;5(1):25-36. doi: 10.1016/j.ddstr.2008.05.006.
8
Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies.GW406381用于治疗膝骨关节炎的评估：两项随机对照研究。
Medscape J Med. 2008;10(11):259. Epub 2008 Nov 12.
9
Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management.外周动脉闭塞性疾病：磁共振成像与积极药物治疗的作用
World J Surg. 2007 Apr;31(4):695-704. doi: 10.1007/s00268-006-0732-y.
10
Promiscuous drugs compared to selective drugs (promiscuity can be a virtue).与选择性药物相比的滥交药物（滥交可能是一种优点）。
BMC Clin Pharmacol. 2005 Apr 26;5:3. doi: 10.1186/1472-6904-5-3.
本文引用的文献
1
Mortality and morbidity after hip fractures.髋部骨折后的死亡率和发病率。
BMJ. 1993 Nov 13;307(6914):1248-50. doi: 10.1136/bmj.307.6914.1248.
2
Pharmacological thromboprophylaxis in hip and knee surgery: a survey of New Zealand orthopaedic surgeons.髋膝关节手术中的药物性血栓预防：新西兰骨科医生的一项调查
Aust N Z J Surg. 1994 Mar;64(3):167-72. doi: 10.1111/j.1445-2197.1994.tb02170.x.
3
Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group.低分子量肝素与标准肝素预防腹部大手术后静脉血栓栓塞。血栓预防协作组。
Lancet. 1993 Jan 30;341(8840):259-65. doi: 10.1016/0140-6736(93)92614-y.
4
Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.抗血小板治疗预防髋部骨折后血栓形成。一项随机试验的理论依据。
J Bone Joint Surg Br. 1994 Jul;76(4):521-4.
5
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?用于血栓预防的抗血小板治疗：是前进还是后退？
BMJ. 1994 Nov 5;309(6963):1213-5. doi: 10.1136/bmj.309.6963.1213.
6
Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.在评估适度治疗效果时避免出现大的偏差和大的随机误差：需要进行系统综述。
Stat Med. 1987 Apr-May;6(3):245-54. doi: 10.1002/sim.4780060308.
7
Why do we need systematic overviews of randomized trials?我们为什么需要随机试验的系统综述？
Stat Med. 1987 Apr-May;6(3):233-44. doi: 10.1002/sim.4780060306.
8
Alpha 1-antitrypsin Pi-types in 965 COPD patients.965例慢性阻塞性肺疾病患者的α1-抗胰蛋白酶Pi型
Chest. 1986 Mar;89(3):370-3. doi: 10.1378/chest.89.3.370.
9
Deep venous thrombosis: a continuing problem.深静脉血栓形成：一个持续存在的问题。
BMJ. 1988 Jul 2;297(6640):28. doi: 10.1136/bmj.297.6640.28.
10
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.围手术期皮下注射肝素可降低致命性肺栓塞和静脉血栓形成的发生率。普通外科、骨科和泌尿外科手术随机试验结果综述。
N Engl J Med. 1988 May 5;318(18):1162-73. doi: 10.1056/NEJM198805053181805.
Zotero 插件